Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GLYC's Cash-to-Debt is ranked higher than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:GLYC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GLYC' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
NAS:GLYC's Interest Coverage is ranked higher than
68% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GLYC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GLYC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 36.01
Beneish M-Score: 472.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -170047.37
NAS:GLYC's Operating Margin % is ranked lower than
99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:GLYC: -170047.37 )
Ranked among companies with meaningful Operating Margin % only.
NAS:GLYC' s Operating Margin % Range Over the Past 10 Years
Min: -170047.37  Med: -116.84 Max: 23.83
Current: -170047.37
-170047.37
23.83
Net Margin % -169405.26
NAS:GLYC's Net Margin % is ranked lower than
99% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:GLYC: -169405.26 )
Ranked among companies with meaningful Net Margin % only.
NAS:GLYC' s Net Margin % Range Over the Past 10 Years
Min: -169405.26  Med: -117.15 Max: 23.96
Current: -169405.26
-169405.26
23.96
ROE % -83.57
NAS:GLYC's ROE % is ranked lower than
72% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:GLYC: -83.57 )
Ranked among companies with meaningful ROE % only.
NAS:GLYC' s ROE % Range Over the Past 10 Years
Min: -137.43  Med: -56.85 Max: 34.84
Current: -83.57
-137.43
34.84
ROA % -71.83
NAS:GLYC's ROA % is ranked lower than
77% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:GLYC: -71.83 )
Ranked among companies with meaningful ROA % only.
NAS:GLYC' s ROA % Range Over the Past 10 Years
Min: -89.49  Med: -29.86 Max: 15.45
Current: -71.83
-89.49
15.45
ROC (Joel Greenblatt) % -4265.78
NAS:GLYC's ROC (Joel Greenblatt) % is ranked lower than
80% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:GLYC: -4265.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GLYC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4265.78  Med: -2266.76 Max: 1059.77
Current: -4265.78
-4265.78
1059.77
3-Year Revenue Growth Rate -83.60
NAS:GLYC's 3-Year Revenue Growth Rate is ranked lower than
91% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:GLYC: -83.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:GLYC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -83.6 Max: -8.6
Current: -83.6
3-Year EBITDA Growth Rate 35.70
NAS:GLYC's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:GLYC: 35.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GLYC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.85 Max: 35.7
Current: 35.7
0
35.7
GuruFocus has detected 4 Warning Signs with GlycoMimetics Inc $NAS:GLYC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GLYC's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GLYC Guru Trades in Q2 2016

Paul Tudor Jones 55,000 sh (New)
Jim Simons 114,600 sh (+65.61%)
» More
Q3 2016

GLYC Guru Trades in Q3 2016

Jim Simons 134,100 sh (+17.02%)
Paul Tudor Jones Sold Out
» More
Q4 2016

GLYC Guru Trades in Q4 2016

Jim Simons 117,900 sh (-12.08%)
» More
Q1 2017

GLYC Guru Trades in Q1 2017

Jim Simons 86,000 sh (-27.06%)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RARX, NAS:NERV, NAS:BSTC, NAS:CRBP, NAS:ABEO, AMEX:BTX, LSE:PRTC, NAS:ASMB, NAS:NVAX, NAS:EDGE, NAS:CORI, NAS:PDLI, NAS:BLCM, NAS:PETX, NAS:NSTG, NAS:CLDX, NAS:CRIS, NAS:CNCE, NAS:SELB, NAS:AVEO » details
Traded in other countries:GKO.Germany,
Headquarter Location:USA
GlycoMimetics Inc is a clinical stage biotechnology company. It is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

Top Ranked Articles about GlycoMimetics Inc

Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.55
GLYC's PB Ratio is ranked lower than
78% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. GLYC: 8.55 )
Ranked among companies with meaningful PB Ratio only.
GLYC' s PB Ratio Range Over the Past 10 Years
Min: 1.81  Med: 3.3 Max: 9.97
Current: 8.55
1.81
9.97
EV-to-EBIT -10.57
GLYC's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. GLYC: -10.57 )
Ranked among companies with meaningful EV-to-EBIT only.
GLYC' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.1  Med: -6.9 Max: -1.8
Current: -10.57
-26.1
-1.8
EV-to-EBITDA -10.63
GLYC's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. GLYC: -10.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLYC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.9  Med: -7 Max: -1.8
Current: -10.63
-26.9
-1.8
Current Ratio 7.78
GLYC's Current Ratio is ranked higher than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. GLYC: 7.78 )
Ranked among companies with meaningful Current Ratio only.
GLYC' s Current Ratio Range Over the Past 10 Years
Min: 2.14  Med: 7.95 Max: 21.83
Current: 7.78
2.14
21.83
Quick Ratio 7.78
GLYC's Quick Ratio is ranked higher than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. GLYC: 7.78 )
Ranked among companies with meaningful Quick Ratio only.
GLYC' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 7.95 Max: 21.83
Current: 7.78
2.14
21.83
Days Sales Outstanding 787.63
GLYC's Days Sales Outstanding is ranked lower than
100% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. GLYC: 787.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLYC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.53  Med: 0.71 Max: 5167.63
Current: 787.63
0.53
5167.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
GLYC's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. GLYC: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLYC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20  Med: -9.8 Max: 0
Current: -9.8
-20
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.28
GLYC's Price-to-Net-Cash is ranked lower than
57% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. GLYC: 9.28 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GLYC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.29  Med: 3.62 Max: 9.28
Current: 9.28
2.29
9.28
Price-to-Net-Current-Asset-Value 9.06
GLYC's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. GLYC: 9.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GLYC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.25  Med: 3.43 Max: 9.06
Current: 9.06
2.25
9.06
Price-to-Tangible-Book 8.55
GLYC's Price-to-Tangible-Book is ranked lower than
70% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. GLYC: 8.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GLYC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 3.31 Max: 8.55
Current: 8.55
2.19
8.55
Price-to-Median-PS-Value 1150.00
GLYC's Price-to-Median-PS-Value is ranked lower than
100% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GLYC: 1150.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLYC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1 Max: 1150
Current: 1150
0.5
1150
Earnings Yield (Greenblatt) % -9.46
GLYC's Earnings Yield (Greenblatt) % is ranked lower than
55% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. GLYC: -9.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLYC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -56  Med: -14.5 Max: -3.8
Current: -9.46
-56
-3.8

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -1.45
Beta3.33
Short Percentage of Float6.53%
52-Week Range $3.82 - 16.94
Shares Outstanding (Mil)32.69

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.35 -1.33 0.28
EPS without NRI ($) -1.35 -1.33 0.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:GLYC

Headlines

Articles On GuruFocus.com
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 

More From Other Websites
GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017 Jul 19 2017
GlycoMimetics to Receive European Patent for GMI-1271 Jul 06 2017
Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Jun 30 2017
GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors Jun 12 2017
Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics Jun 07 2017
GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference Jun 05 2017
Why GlycoMimetics Is Tumbling 13.4% Today Jun 05 2017
GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients... Jun 05 2017
GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of... May 31 2017
GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to... May 30 2017
Here's Why GlycoMimetics Rose as Much as 21% Today May 25 2017
GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia May 25 2017
GlycoMimetics Announces Pricing of Public Offering of Common Stock May 24 2017
Shark Bites: There Wasn't Even a Dip to Buy May 23 2017
GlycoMimetics Announces Proposed Public Offering of Common Stock May 22 2017
Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics May 22 2017
ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017 May 19 2017
Why GlycoMimetics Is Ripping 19% Higher Today May 19 2017
GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7% May 19 2017
Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix May 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}